glp 1 summit Home Employer Coverage of GLP-1 Drugs

53.European Medicines Agency SitagliptinScientific Conclusions and Grounds Recommending the Variation to the Terms of the Marketing Authorisation

patients with pre-existing retinopathy should undergo ophthalmologic monitoring

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

We cannot teach all young girls that their bodies are incapable of finding balance, a message that cuts off the larger health-care journey

doi: 10.1016/j.atherosclerosis.2017.04.001 131 PoulterNRPrabhakaranDCaulfieldM